Saffron supplement improves retinal flicker sensitivity

Article

Short-term saffron supplementation has been found to improve retinal flicker sensitivity in early age-related macular degeneration (AMD).

Short-term saffron supplementation has been found to improve retinal flicker sensitivity in early age-related macular degeneration (AMD), according to a study recently published in Investigative Ophthalmology & Visual Science.

The study, led by Dr Benedetto Falsini of the Universita' Cattolica del S. Cuore, Rome, Italy, aimed to evaluate the functional effect that short-term saffron supplementation may have on early AMD.

A group of 25 patients with AMD were randomly assigned to oral saffron 20 mg/d or placebo supplementation for 3 months and then reverted to the reverse treatment for another 3 months. Focal electroretinograms (fERGs) and clinical findings were recorded at baseline and then after 3 months of treatment with saffron or placebo supplementation.

After the patients had received saffron supplementation their fERGs increased in amplitude compared with the baseline or those on the placebo treatment. Additionally, the fERG thresholds were decreased after saffron supplementation but not placebo.

These results show that the short-term use of saffron supplementation improves retinal flicker sensitivity in early AMD. However, these results need to be replicate and the clinical significance has not yet been quantified. Overall, the study has provided important clues that the nutritional carotenoids found in saffron may affect AMD in ways that may be beyond their antioxidant properties.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.